Augmentin Tab 250 mg, 125 mg Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

augmentin tab 250 mg, 125 mg

مستودع أدوية سليمان طنوس وأولاده - suleiman tannous & sons co. ltd - amoxicillin 250 mg, clavulanic acid 125 mg - 250 mg, 125 mg

Augmentin Tab 500 mg, 125 mg Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

augmentin tab 500 mg, 125 mg

مستودع أدوية سليمان طنوس وأولاده - suleiman tannous & sons co. ltd - amoxicillin 500 mg, clavulanic acid 125 mg - 500 mg, 125 mg

Augmentin 156 Susp. 125 mg/5ml, 31.25 mg/5ml Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

augmentin 156 susp. 125 mg/5ml, 31.25 mg/5ml

مستودع أدوية سليمان طنوس وأولاده - suleiman tannous & sons co. ltd - amoxicillin 125 mg/5ml, clavulanic acid 31.25 mg/5ml - 125 mg/5ml, 31.25 mg/5ml

Augmentin 312 Susp. 250 mg/5ml, 62.5 mg/5ml Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

augmentin 312 susp. 250 mg/5ml, 62.5 mg/5ml

مستودع أدوية سليمان طنوس وأولاده - suleiman tannous & sons co. ltd - amoxicillin 250 mg/5ml, clavulanic acid 62.5 mg/5ml - 250 mg/5ml, 62.5 mg/5ml

Dermovate Cream 0.05%w/w Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

dermovate cream 0.05%w/w

مستودع أدوية سليمان طنوس وأولاده - suleiman tannous & sons co. ltd - clobetasol propionate 0.05 %w/w - 0.05%w/w

REMSIMA 120 MGML S.C. Israel - English - Ministry of Health

remsima 120 mgml s.c.

padagis israel agencies ltd, israel - infliximab - solution for injection - infliximab 120 mg/ml - infliximab - rheumatoid arthritis: remsima, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in:•adult patients with active disease when the response to disease-modifying antirheumatic drugs (dmards),including methotrexate, has been inadequate. •adult patients with severe, active and progressive disease not previously treated with methotrexate or other dmards. in these patient populations, a reduction in the rate of the progression of joint damage, as measured by x ray,has been demonstrated.crohn’s diseaseremsima is indicated for:• treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.• treatment of fistulising, active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).ulcerative colitisremsima is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies.ankylosing spondylitisremsima is indicated for treatment of severe, active ankylosing spondylitis, in adult patients who have responded inadequately to conventional therapy.psoriatic arthritisremsima is indicated for treatment of active and progressive psoriatic arthritis in adult patients when the response to previous dmard therapy has been inadequate.remsima should be administered• in combination with methotrexate• or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated. infliximab has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease.psoriasisremsima is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or psoralen ultra-violet a (puva).

Esmeron 50 mg/5ml Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

esmeron 50 mg/5ml

مستودع أدوية أداتكو - adatco drug store - rocuronium bromide 50 mg/5ml - 50 mg/5ml

PRIMOLUT DEPOT Amp 250 mg Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

primolut depot amp 250 mg

شركة مستودع الأدوية الأردني - the jordan drugstore co - hydroxyprogesterone caproate 250 mg - 250 mg

VOTRIENT 200 MG Israel - English - Ministry of Health

votrient 200 mg

novartis israel ltd - pazopanib as hydrochloride - film coated tablets - pazopanib as hydrochloride 200 mg - pazopanib - pazopanib - renal cell carcinoma (rcc)votrient is indicated in adults for the first line treatment of advanced renal cell carcinoma (rcc) and for patients who have received prior cytokine therapy for advanced disease.soft tissue sarcoma (sts)votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (sts) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.

VOTRIENT 400 MG Israel - English - Ministry of Health

votrient 400 mg

novartis israel ltd - pazopanib as hydrochloride - film coated tablets - pazopanib as hydrochloride 400 mg - pazopanib - pazopanib - renal cell carcinoma (rcc)votrient is indicated in adults for the first line treatment of advanced renal cell carcinoma (rcc) and for patients who have received prior cytokine therapy for advanced disease.soft tissue sarcoma (sts)votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (sts) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.